Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study
This study offers a preliminary exploration of the potential exposure-efficacy and exposure-safety relationships of VEN combined with HMAs for the treatment of MDS in Chinese patients. Given the interindividual variability in VEN exposure, therapeutic drug monitoring is recommended as an essential part of clinical practice in MDS treatment. Future research is necessary to conduct more in-depth and large-scale analyses to determine the optimal exposure threshold for VEN.
Authors
- Yi-Ying Liu
- Ji-Xin Tian
- Wenjuan Miao
- Zhijian Xiao (ORCID: https://orcid.org/0000-0002-1099-4489)
- Dongxue Liu (ORCID: https://orcid.org/0000-0001-7008-878X)
- Xiaoxu Wang (ORCID: https://orcid.org/0000-0002-4291-0729)
- Ping Zhang (ORCID: https://orcid.org/0000-0002-4585-9893)
- Jinwen Li (ORCID: https://orcid.org/0009-0007-2705-1368)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.3389/fphar.2025.1586910
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Tianjin Medical University